High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy - Mitra, Devarati; Horick, Nora K.; Brackett, Diane G.; Mouw, Kent W.; Hornick, Jason L.; Ferrone, Soldano; Hong, Theodore S.; Mamon, Harvey; Clark, Jeffrey W.; Parikh, Aparna R.; Allen, Jill N.; Ryan, David P.; et al. (The oncologist (Dayton, Ohio), 2019)
Keywords: Adult; Aged; Aged, 80 and over; Anal Canal - pathology; Anal cancer; Anus Neoplasms - immunology; Anus Neoplasms - mortality; Anus Neoplasms - pathology; Anus Neoplasms - therapy; Biomarkers, Tumor - immunology; Biomarkers, Tumor - metabolism; Chemoradiation; Chemoradiotherapy; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Cancer; Histocompatibility Antigens Class I - immunology; Histocompatibility Antigens Class I - metabolism; Humans; Immune microenvironment; Indoleamine 2,3 dioxygenase 1; Indoleamine-Pyrrole 2,3,-Dioxygenase - immunology; Indoleamine-Pyrrole 2,3,-Dioxygenase - metabolism; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - immunology; Neoplasm Recurrence, Local - pathology; Outcomes; Prognosis; Retrospective Studies; Tumor Escape; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology; Tumor Microenvironment - radiation effects; Immune microenvironment; Anal cancer; Chemoradiation; Indoleamine 2,3 dioxygenase 1; Outcomes